What's New @ FORCE
- ABOUT Network
- Patient Centered and Real World Research
- 2014 Conference
- Live Life Empowered
- Uncertain or Negative Results
- Free the Data
- Research Update
- Voices of FORCE
- Matching Participants to Clinical Trials
- Weighing the Evidence
- What's New @ FORCE
On June 25, the Oncologic Drugs Advisory Committee (ODAC) of the FDA will discuss AstraZeneca Pharmaceuticals’ new drug application for olaparib (a PARP inhibitor) capsules as maintenance treatment of patients with platinumsensitive relapsed ovarian cancer who have completed chemotherapy. The public meeting will take place at the FDA offices outside of Washington, D.C. PARP inhibitors were developed specifically for the treatment of cancers associated with a BRCA genetic mutation.
FORCE has been a strong proponent of PARP inhibitor research, and we will present oral commentary supporting approval of this application. We are hopeful that olaparib will be approved as a new agent for women fighting hereditary ovarian cancer. Here is a link to FORCE's testimony statement.
The committee meeting will be webcast. Read more about the meeting on the FDA website.
Join Team FORCE
Get ready to get fit! Put your training, passion, and commitment to fitness to work for a good cause: raising funds for FORCE. Team FORCE is a community of athletes and fitness enthusiasts dedicated to supporting the hereditary breast and ovarian cancer community. These women and men commit their training and participation in races, marathons and other athletic events to raise much-needed funds for FORCE. Team FORCE provides a great opportunity to have a positive impact on FORCE’s ability to fulfill our mission by leveraging your personal fitness efforts. Visit facingourrisk.org/teamforce to join Team FORCE.
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.